share_log

和鉑醫藥-B：截至二零二三年十二月三十一日止之股份發行人的證券變動月報表

HBM HOLDINGS-B: Monthly Return of Equity Issuer on Movements in Securities for the month ended 31 December 2023

香港交易所 ·  Jan 5 05:51
Summary by Moomoo AI
和鉑醫藥控股有限公司（和铂医药-B）於2024年1月5日向香港交易及結算所有限公司提交了截至2023年12月31日的證券變動月報表。報告顯示，公司的法定/註冊股本維持不變，上月底結存及本月底結存均為20,000,000,000股，面值0.000025美元，總額500,000美元。在股份期權方面，首次公開發售後購股權計劃在本月內無新增股份期權，但有155,400股份期權失效，使得本月底結存的股份期權數目為38,187,950股。此外，首次公開發售後股份獎勵計劃在2023年8月及9月有股份獎勵失效，並已於之前的月報表中反映。公司亦報告了在2023年6月8日購回1,750,000股普通股的情況。報告由執行董事王勁松呈交，並確認所有證券發行均獲董事會授權且符合相關法律規定。
和鉑醫藥控股有限公司（和铂医药-B）於2024年1月5日向香港交易及結算所有限公司提交了截至2023年12月31日的證券變動月報表。報告顯示，公司的法定/註冊股本維持不變，上月底結存及本月底結存均為20,000,000,000股，面值0.000025美元，總額500,000美元。在股份期權方面，首次公開發售後購股權計劃在本月內無新增股份期權，但有155,400股份期權失效，使得本月底結存的股份期權數目為38,187,950股。此外，首次公開發售後股份獎勵計劃在2023年8月及9月有股份獎勵失效，並已於之前的月報表中反映。公司亦報告了在2023年6月8日購回1,750,000股普通股的情況。報告由執行董事王勁松呈交，並確認所有證券發行均獲董事會授權且符合相關法律規定。
PLATINUM PHARMACEUTICALS HOLDINGS LIMITED (AND PLATINUM PHARMACEUTICALS -B) FILED WITH HONG KONG TRADING AND SETTLEMENT HOLDINGS LIMITED ON JANUARY 5, 2024 THE REPORT OF CHANGES IN SECURITIES FOR THE MONTH ENDED DECEMBER 31, 2023. The report shows that the company's regulated/registered share capital remained unchanged, with 20,000,000,000 shares outstanding at the end of last month and deposits at the end of this month at $0.000025 for a total of $500,000. In terms of stock options, the share option plan after the initial public offering did not add stock options during the month, but 155,400 share options expired, bringing the number of stock options outstanding at the end of the month to 38,187,950 shares. In addition, the share award scheme after the initial public offering has expired in...Show More
PLATINUM PHARMACEUTICALS HOLDINGS LIMITED (AND PLATINUM PHARMACEUTICALS -B) FILED WITH HONG KONG TRADING AND SETTLEMENT HOLDINGS LIMITED ON JANUARY 5, 2024 THE REPORT OF CHANGES IN SECURITIES FOR THE MONTH ENDED DECEMBER 31, 2023. The report shows that the company's regulated/registered share capital remained unchanged, with 20,000,000,000 shares outstanding at the end of last month and deposits at the end of this month at $0.000025 for a total of $500,000. In terms of stock options, the share option plan after the initial public offering did not add stock options during the month, but 155,400 share options expired, bringing the number of stock options outstanding at the end of the month to 38,187,950 shares. In addition, the share award scheme after the initial public offering has expired in August and September 2023 and has been reflected in the previous monthly report. The company also reported the repurchase of 1,750,000 shares of ordinary shares on June 8, 2023. The report is submitted by Executive Director Wang Jinsong, confirming that all securities issuance is authorized by the Board of Directors and in compliance with relevant legal requirements.

This announcement is a separate document:

Doc 1     View Translation

Disclaimer: This content is for informational and educational purposes only and does not constitute a recommendation or endorsement of any specific investment or investment strategy. Read more